Welcome to CDC stacks | Atomoxetine Increases Fronto-Parietal Functional MRI Activation in Attention-Deficit/Hyperactivity Disorder: A Pilot Study - 41876 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Atomoxetine Increases Fronto-Parietal Functional MRI Activation in Attention-Deficit/Hyperactivity Disorder: A Pilot Study
Filetype[PDF-1.15 MB]


Details:
No Related Documents.
You May Also Like:
  1. Speed and Complexity Characterize Attention Problems in Children with Localization-Related Epilepsy
    Personal Author:
    Berl, Madison; Terwilliger, Virginia; Scheller, Alexandra; Sepeta, Leigh; Walkowiak, Jenifer; Gaillard, William D.;
    Published:
    May 04 2015
    Source:
    Epilepsia. 56(6):833-840.
    Description:
    Objective : Children with epilepsy (EPI) have a higher rate of ADHD (28–70%) than typically developing (TD) children (5–10%); however, attention is multidimensional. Thus, we aimed to characterize the profile of attention difficulties in children...
    File Type:
    Filetype[PDF - 312.76 KB]
  2. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
    Corporate Author:
    SUBCOMMITTEE ON ATTENTION-DEFICIT/HYPERACTIVITY DISORDER, STEERING COMMITTEE ON QUALITY IMPROVEMENT AND MANAGEMENT
    Published:
    Oct 16 2011
    Source:
    Pediatrics. 2011; 128(5):1007-1022
    Description:
    Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder of childhood and can profoundly affect the academic achievement, well-being, and social interactions of children; the American Academy of Pediatrics first pub...
    File Type:
    Filetype[PDF - 349.97 KB]
  3. Immune mediated Disorders in Women with a Fragile X Expansion and FXTAS
    Personal Author:
    Jalnapurkar, Isha; Rafika, Nuva; Tassone, Flora; Hagerman, Randi;
    Published:
    Nov 14 2014
    Source:
    Am J Med Genet A. 0(1):190-197.
    Description:
    Premutation alleles in fragile X mental retardation 1 (FMR1) can cause the late-onset neurodegenerative disorder, fragile X-associated tremor ataxia syndrome (FXTAS) and/or the fragile X-associated primary ovarian insufficiency in approximately 20% o...
    File Type:
    Filetype[PDF - 368.32 KB]
  4. Fragile X Syndrome and Targeted Treatment Trials
    Personal Author:
    Hagerman, Randi; Lauterborn, Julie; Au, Jacky; Berry-Kravis, Elizabeth;
    Published:
    2012
    Source:
    Results Probl Cell Differ. 2012; 54:297-335.
    Description:
    Work in recent years has revealed an abundance of possible new treatment targets for fragile X syndrome (FXS). The use of animal models, including the fragile X knockout mouse which manifests a phenotype very similar to FXS in humans, has resulted in...
    File Type:
    Filetype[PDF - 152.73 KB]
  5. Coming Soon
    Age- and CGG Repeat-Related Slowing of Manual Movement in Fragile X Carriers: A Prodrome of FXTAS?
    Personal Author:
    Shickman, Ryan; Famula, Jessica; Tassone, Flora; Leehey, Maureen; Ferrer, Emilio; Rivera, Susan M.; Hessl, David;
    Published:
    Feb 01 2018
    Source:
    Mov Disord. 33(4):628-636.
    Description:
    Background : Fragile X premutation carriers are at increased risk for fragile X-associated tremor ataxia syndrome (FXTAS), but to date we know little about prediction of onset and rate of progression, and even less about treatment of this neurodegene...
    Public Access
    Available on:
    April 01, 2019